Valeant Said in Advanced Talks to Buy Egypt Drugmaker Amoun

Valeant Pharmaceuticals International Inc. is in advanced negotiations to acquire Egyptian drugmaker Amoun Pharmaceutical Co. as it seeks to expand into emerging markets, according to people with knowledge of the matter.

The drugmaker, based in Laval, Quebec, may reach an agreement with Amoun’s shareholders in the coming weeks, the people said, asking not to be identified as the information is private. No final decision has been made and any deal may still fall apart, they said.

A sale of Amoun could value the company at $700 million to $800 million, people familiar with the matter said in May.